Melanotan II Evidence Guide
Evidence for Melanotan II is too preliminary to support a research protocol with confidence, and its safety profile is a genuine concern - not approved by any regulatory agency, associated with spontaneous erections, blood pressure changes, nausea, and multiple case reports of melanoma in pre-existing nevi. Of the Sexual Health compounds, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire and has a far superior safety and evidence profile.
Our Take
Evidence for Melanotan II is too preliminary to support a research protocol with confidence, and its safety profile is a genuine concern - not approved by any regulatory agency, associated with spontaneous erections, blood pressure changes, nausea, and multiple case reports of melanoma in pre-existing nevi. Of the Sexual Health compounds, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire and has a far superior safety and evidence profile.
- Best for
- No validated therapeutic application - melanocortin receptor pharmacology research (with caution)
- Evidence grade
- Level C
- Confidence
- Low
- Starting point
- No safe established human protocol - regulatory agencies have not approved this compound
Benefits and Evidence
- Skin Pigmentation: Level C, includes human evidence - Clinical trials demonstrated significant skin darkening with subcutaneous MT-II administration. Pigmentation occurs without UV exposure, though UV co-exposure enhances results.
- Erectile Function: Level C, includes human evidence - Wessells et al. (2000, Int J Impot Res) reported that SC melanotan II (0.025 mg/kg) induced erections in 12/19 men within 1-5 h, with 8/10 erectile dysfunction patients showing improved rigidity; Dorr et al. (1996, Life Sci) first documented spontaneous erections in Phase I melanoma-tanning trials, leading to bremelanotide (PT-141) development.
- Nausea & Side Effects: Level C, includes human evidence - Facial flushing, nausea, and fatigue are commonly reported. Mole darkening and potential for melanoma concern have been raised in case reports.
Side Effects and Warnings
- Nausea and facial flushing
- Darkening of existing moles and nevi
- Fatigue and drowsiness
- Spontaneous erections
- Elevated blood pressure
- Injection site reactions
- Not approved by any regulatory agency for human use
- Potential risk of melanoma promotion due to melanocyte stimulation - patients with family history should avoid
Research Dosage References
- <strong>Subcutaneous injection</strong> - 0.25-1.0 mg - Daily during loading, then weekly maintenance - Not approved for human use. Doses referenced from clinical research only. Loading phase typically 0.5 mg/day for 5-7 days.
- <strong>Nasal spray</strong> - 0.5-1.0 mg - As studied in research settings - Lower bioavailability than injection. Nasal formulations have been studied but not approved.
Mechanism of Action
Melanotan II acts as a non-selective agonist of melanocortin receptors (MC1R-MC5R): 1. MC1R activation: Stimulates melanogenesis in melanocytes, increasing eumelanin production and skin pigmentation without UV exposure. 2. MC3R/MC4R activation: Produces effects on sexual function through central nervous system pathways, increasing libido and facilitating erections. 3. MC4R-mediated appetite suppression: Reduces food intake through hypothalamic melanocortin signaling. 4. Cardiovascular effects: MC receptor activation can cause transient increases in blood pressure and heart rate.
Legal Status
Not FDA-approved. Classified as an unscheduled research peptide in the United States. Banned for sale as a consumer product in many countries including Australia and the UK. Prohibited by WADA in competitive sports.
Primary Sources
- Subcutaneous administration of melanotan II to human volunteers: a phase I study. Journal of Clinical Pharmacology, 1996.
- Melanotan II: an investigation of usage, effects, and safety. Drug Testing and Analysis, 2012.
- Melanocortin receptor agonists and antagonists in the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 2003.